ProCE Banner Activity

Existing and Emerging Clinical Data of Available PI3K Inhibitors Used for the Treatment of R/R FL

Slideset Download
Download this slideset on existing and emerging clinical data of available PI3K inhibitors for patients with relapsed and refractory follicular lymphoma.

Released: June 17, 2021

Expiration: June 16, 2022

No longer available for credit.

Share

Faculty

Nathan H. Fowler

Nathan H. Fowler, MD

Associate Professor
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

TG Therapeutics

Faculty Disclosure

Primary Author

Nathan H. Fowler, MD

Associate Professor
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas